Harbin Gloria Pharmaceuticals (002437) - Net Assets
Based on the latest financial reports, Harbin Gloria Pharmaceuticals (002437) has net assets worth CN¥2.41 Billion CNY (≈ $352.02 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.14 Billion ≈ $459.71 Million USD) and total liabilities (CN¥735.96 Million ≈ $107.69 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how tangible is Harbin Gloria Pharmaceuticals's equity to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.41 Billion |
| % of Total Assets | 76.57% |
| Annual Growth Rate | 16.93% |
| 5-Year Change | 16.71% |
| 10-Year Change | -42.93% |
| Growth Volatility | 145.83 |
Harbin Gloria Pharmaceuticals - Net Assets Trend (2007–2025)
This chart illustrates how Harbin Gloria Pharmaceuticals's net assets have evolved over time, based on quarterly financial data. See 002437 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Harbin Gloria Pharmaceuticals (2007–2025)
The table below shows the annual net assets of Harbin Gloria Pharmaceuticals from 2007 to 2025. For live valuation and market cap data, see Harbin Gloria Pharmaceuticals stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.31 Billion ≈ $337.96 Million |
+17.07% |
| 2024-12-31 | CN¥1.97 Billion ≈ $288.69 Million |
+15.36% |
| 2023-12-31 | CN¥1.71 Billion ≈ $250.26 Million |
+0.39% |
| 2022-12-31 | CN¥1.70 Billion ≈ $249.28 Million |
-13.92% |
| 2021-12-31 | CN¥1.98 Billion ≈ $289.58 Million |
+2.38% |
| 2020-12-31 | CN¥1.93 Billion ≈ $282.85 Million |
+21.68% |
| 2019-12-31 | CN¥1.59 Billion ≈ $232.45 Million |
-63.85% |
| 2018-12-31 | CN¥4.39 Billion ≈ $642.95 Million |
+3.32% |
| 2017-12-31 | CN¥4.25 Billion ≈ $622.28 Million |
+5.09% |
| 2016-12-31 | CN¥4.05 Billion ≈ $592.15 Million |
+16.52% |
| 2015-12-31 | CN¥3.47 Billion ≈ $508.18 Million |
+11.95% |
| 2014-12-31 | CN¥3.10 Billion ≈ $453.95 Million |
+25.17% |
| 2013-12-31 | CN¥2.48 Billion ≈ $362.66 Million |
+4.98% |
| 2012-12-31 | CN¥2.36 Billion ≈ $345.46 Million |
+7.44% |
| 2011-12-31 | CN¥2.20 Billion ≈ $321.54 Million |
+3.61% |
| 2010-12-31 | CN¥2.12 Billion ≈ $310.33 Million |
+637.57% |
| 2009-12-31 | CN¥287.53 Million ≈ $42.07 Million |
+48.18% |
| 2008-12-31 | CN¥194.04 Million ≈ $28.39 Million |
+40.24% |
| 2007-12-31 | CN¥138.36 Million ≈ $20.25 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Harbin Gloria Pharmaceuticals's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 434.5% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CN¥2.60 Billion | 113.28% |
| Total Equity | CN¥2.29 Billion | 100.00% |
Harbin Gloria Pharmaceuticals Competitors by Market Cap
The table below lists competitors of Harbin Gloria Pharmaceuticals ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Suning Universal Co Ltd
SHE:000718
|
$861.48 Million |
|
EQ Resources Ltd
AU:EQR
|
$861.94 Million |
|
BeiJing Certificate Authority Co Ltd
SHE:300579
|
$862.10 Million |
|
Myers Industries Inc
NYSE:MYE
|
$862.32 Million |
|
Center Laboratories
TWO:4123
|
$861.39 Million |
|
Shenzhen Sosen Electronics Co.Ltd.
SHE:301002
|
$861.25 Million |
|
Seneca Foods Corp A
NASDAQ:SENEA
|
$861.22 Million |
|
Tongyang Life
KO:082640
|
$860.90 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Harbin Gloria Pharmaceuticals's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,950,697,287 to 2,293,671,990, a change of 342,974,703 (17.6%).
- Net income of 376,905,170 contributed positively to equity growth.
- Dividend payments of 1,209,292 reduced retained earnings.
- Other comprehensive income increased equity by 3,086,204.
- Other factors decreased equity by 35,807,379.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥376.91 Million | +16.43% |
| Dividends Paid | CN¥1.21 Million | -0.05% |
| Other Comprehensive Income | CN¥3.09 Million | +0.13% |
| Other Changes | CN¥-35.81 Million | -1.56% |
| Total Change | CN¥- | 17.58% |
Book Value vs Market Value Analysis
This analysis compares Harbin Gloria Pharmaceuticals's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.57x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 30.04x to 2.57x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | CN¥0.09 | CN¥2.64 | x |
| 2008-12-31 | CN¥0.12 | CN¥2.64 | x |
| 2009-12-31 | CN¥0.18 | CN¥2.64 | x |
| 2010-12-31 | CN¥1.15 | CN¥2.64 | x |
| 2011-12-31 | CN¥1.04 | CN¥2.64 | x |
| 2012-12-31 | CN¥1.11 | CN¥2.64 | x |
| 2013-12-31 | CN¥1.13 | CN¥2.64 | x |
| 2014-12-31 | CN¥1.43 | CN¥2.64 | x |
| 2015-12-31 | CN¥1.55 | CN¥2.64 | x |
| 2016-12-31 | CN¥1.80 | CN¥2.64 | x |
| 2017-12-31 | CN¥1.90 | CN¥2.64 | x |
| 2018-12-31 | CN¥1.97 | CN¥2.64 | x |
| 2019-12-31 | CN¥0.69 | CN¥2.64 | x |
| 2020-12-31 | CN¥0.84 | CN¥2.64 | x |
| 2021-12-31 | CN¥0.86 | CN¥2.64 | x |
| 2022-12-31 | CN¥0.74 | CN¥2.64 | x |
| 2023-12-31 | CN¥0.76 | CN¥2.64 | x |
| 2024-12-31 | CN¥0.86 | CN¥2.64 | x |
| 2025-12-31 | CN¥1.03 | CN¥2.64 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Harbin Gloria Pharmaceuticals utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 16.43%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 17.65%
- • Asset Turnover: 0.68x
- • Equity Multiplier: 1.37x
- Recent ROE (16.43%) is above the historical average (5.93%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 54.05% | 45.55% | 0.76x | 1.56x | CN¥60.93 Million |
| 2008 | 54.60% | 38.44% | 0.99x | 1.44x | CN¥86.55 Million |
| 2009 | 45.29% | 30.29% | 0.97x | 1.54x | CN¥101.48 Million |
| 2010 | 7.30% | 26.89% | 0.26x | 1.03x | CN¥-57.36 Million |
| 2011 | 5.39% | 21.39% | 0.24x | 1.07x | CN¥-99.96 Million |
| 2012 | 7.06% | 23.17% | 0.28x | 1.10x | CN¥-68.52 Million |
| 2013 | 9.48% | 17.34% | 0.44x | 1.23x | CN¥-12.37 Million |
| 2014 | 14.69% | 23.28% | 0.39x | 1.63x | CN¥141.65 Million |
| 2015 | 19.54% | 24.79% | 0.32x | 2.44x | CN¥324.50 Million |
| 2016 | 18.08% | 24.02% | 0.34x | 2.19x | CN¥320.34 Million |
| 2017 | 7.42% | 10.18% | 0.34x | 2.17x | CN¥-107.72 Million |
| 2018 | 2.91% | 2.30% | 0.58x | 2.19x | CN¥-306.51 Million |
| 2019 | -174.96% | -52.67% | 0.79x | 4.21x | CN¥-2.81 Billion |
| 2020 | 21.67% | 13.10% | 0.68x | 2.45x | CN¥215.43 Million |
| 2021 | 2.38% | 1.43% | 0.67x | 2.48x | CN¥-144.38 Million |
| 2022 | -17.86% | -9.37% | 0.76x | 2.50x | CN¥-454.45 Million |
| 2023 | 7.24% | 4.58% | 0.83x | 1.90x | CN¥-45.84 Million |
| 2024 | 11.93% | 9.54% | 0.86x | 1.45x | CN¥37.69 Million |
| 2025 | 16.43% | 17.65% | 0.68x | 1.37x | CN¥147.54 Million |
Industry Comparison
This section compares Harbin Gloria Pharmaceuticals's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,819,786,107
- Average return on equity (ROE) among peers: 5.04%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Harbin Gloria Pharmaceuticals (002437) | CN¥2.41 Billion | 54.05% | 0.31x | $861.43 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $5.88 Billion | 7.12% | 1.83x | $612.18 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $536.15 Million | 4.62% | 0.32x | $371.95 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $0.00 | 0.00% | 0.00x | $4.52 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $13.64 Billion | 12.57% | 0.51x | $2.56 Billion |
| Wedge Industrial Co Ltd (000534) | $549.14 Million | 1.31% | 0.01x | $2.22 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $893.64 Million | 25.78% | 0.79x | $12.90 Billion |
| Hainan Haiyao Co Ltd (000566) | $5.08 Billion | 1.71% | 1.08x | $734.70 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $271.26 Million | 1.07% | 1.01x | $324.84 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $1.60 Billion | -10.44% | 3.72x | $929.28 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $9.75 Billion | 6.63% | 0.12x | $3.13 Billion |
About Harbin Gloria Pharmaceuticals
HARBIN GLORIA PHARMACEUTICALS Co., LTD engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. Its products include cardiovascular and cerebrovascular, musculoskeletal, vitamins, electrolyte, diabetes-lowering, analgesics, digestive system and metabolism, anti-infective, and anti-tumor drugs. Harbin Gloria Pharmaceuticals Co., Ltd w… Read more